GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
|Poll|April 1, 2015
Mini Quiz: Metabolic Monitoring in Serious Mental Illness
Author(s)Psychiatric Times Editors
Listen
0:00 / 0:00
Key Takeaways
- Antipsychotic medications increase the risk of metabolic syndrome, necessitating regular monitoring for early detection and management of side effects.
- Metabolic monitoring helps prevent cardiovascular diseases and diabetes by addressing weight gain, dyslipidemia, and insulin resistance.
Advertisement
What is the rationale for metabolic monitoring in serious mental illness? Take the quiz and learn more.
Which of the following is a rationale for metabolic monitoring in serious mental illness?
Advertisement
Related to this article
A Delphi panel recommends screening for eating disorders before GLP-1 receptor agonist initiation.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology
3
Schizophrenia: A Telltale of the Brain’s Complexity
4
Podcast: Interventional Psychiatry and the Challenge of Difficult-to-Treat Depression
5